Woodline Partners LP Has $11.22 Million Holdings in MBX Biosciences, Inc. (NYSE:MBX)

Woodline Partners LP boosted its stake in MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 17.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 608,721 shares of the company's stock after buying an additional 89,046 shares during the period. Woodline Partners LP owned 1.82% of MBX Biosciences worth $11,219,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in MBX. BNP Paribas Financial Markets acquired a new position in shares of MBX Biosciences during the fourth quarter valued at $27,000. Virtus ETF Advisers LLC acquired a new position in shares of MBX Biosciences during the fourth quarter valued at $64,000. Deutsche Bank AG acquired a new position in shares of MBX Biosciences during the fourth quarter valued at $80,000. Corebridge Financial Inc. acquired a new position in shares of MBX Biosciences during the fourth quarter valued at $103,000. Finally, Wells Fargo & Company MN acquired a new position in shares of MBX Biosciences during the fourth quarter valued at $108,000.

Insider Buying and Selling at MBX Biosciences

In other MBX Biosciences news, Director Ora H. Pescovitz purchased 7,693 shares of the business's stock in a transaction on Tuesday, April 8th. The stock was bought at an average cost of $5.89 per share, with a total value of $45,311.77. Following the acquisition, the director now owns 24,329 shares of the company's stock, valued at $143,297.81. The trade was a 46.24% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 52.19% of the stock is owned by corporate insiders.

MBX Biosciences Price Performance

NYSE MBX traded down $0.17 on Wednesday, reaching $12.43. The company's stock had a trading volume of 32,227 shares, compared to its average volume of 289,461. MBX Biosciences, Inc. has a twelve month low of $4.81 and a twelve month high of $27.50. The firm's 50 day moving average is $9.10 and its two-hundred day moving average is $12.67.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MBX. Guggenheim reissued a "buy" rating and set a $44.00 price target on shares of MBX Biosciences in a report on Thursday, April 10th. JMP Securities assumed coverage on shares of MBX Biosciences in a report on Thursday, April 10th. They issued a "market outperform" rating and a $38.00 price objective for the company. Finally, Citizens Jmp assumed coverage on shares of MBX Biosciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $38.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $37.50.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.